For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters.

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...

IT’S that time of year where parents brace themselves for an onslaught of winter bugs. With health bosses warning of a spike ...

A study has highlighted ways to reduce RSV infections - including a vaccine programme which could reduce antibiotic ...

Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for ...

Public health officials reiterated the importance of vaccines after seeing a rise in circulating levels of respiratory syncytial virus (RSV).

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

“It is a good idea to get your flu jab every year and to make sure you have the pneumonia vaccine, Covid-19 vaccination and the RSV vaccination if you are eligible,” recommends Whittamore. “Make sure ...

Health Canada approves Moderna’s RSV vaccine, mRESVIA for adults aged 60 years and older: Cambridge, Massachusetts Monday, November 11, 2024, 12:00 Hrs [IST] Moderna, Inc., a le ...